On Wednesday, BofA Securities updated its outlook on Danaher Corporation (NYSE:DHR), a global science and technology innovator. The firm's analyst increased the price target for Danaher to $270 from ...
In a recent transaction, Brian W. Ellis, Senior Vice President and General Counsel of Danaher Corp (NYSE:DHR), sold 4,000 shares of the company's common stock. The sale, which took place on April 24, ...
On Wednesday, Baird expressed a positive outlook on Danaher Corporation (NYSE: NYSE:DHR), raising the stock's price target to $271 from $259, while reiterating an Outperform rating. The adjustment ...
Danaher Corporation (NYSE:DHR) Q1 2024 Earnings Call Transcript April 23, 2024 Danaher Corporation misses on earnings expectations. Reported EPS is $1.45 EPS, expectations were $1.72. Operator: Hello.
Douglas Schenkel: Super helpful, Rainer. One very quick unrelated follow-up. I think as we sit here today, Danaher probably has $30 billion, maybe as much as $40 billion if you stretched for the ...
Currently, the analyst consensus on Danaher is a Strong Buy with an average price target of $275.50, an 8.2% upside from current levels. In a report issued on April 10, Barclays also maintained a ...
And any comments on cancellation trends would be great. A: Rainer M. Blair, President and CEO of Danaher, noted that the bioprocessing business had a better-than-expected start, with mid-single digits ...
Danaher Corporation’s DHR first-quarter 2024 adjusted earnings (excluding 47 cents from non-recurring items) of $1.92 per share surpassed the Zacks Consensus Estimate of $1.72. The bottom line ...
Everton is actively pursuing third-party investment to facilitate the completion of a prolonged takeover by 777 Partners, a Miami-based investment firm. Although a deal was agreed upon in ...
For the quarter ended March 2024, Danaher (DHR) reported revenue of $5.8 billion, down 19.1% over the same period last year. EPS came in at $1.92, compared to $2.36 in the year-ago quarter.
Danaher (NYSE:DHR) shares added ~9% premarket Tuesday after the company topped Street forecasts with its Q1 2024 financials despite ongoing contraction at its biotech business. The U.S.-based life ...